Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Sermorelin vs Tesamorelin: Research Protocol Comparison

Primary Mechanism Direct GHRH receptor agonism → pulsatile GH release from anterior pituitary Modified GHRH analog with enhanced receptor affinity + tissue-specific lipolytic signaling Tesamorelin's structural modification creates dual-action profile sermoreli

This comparison does not assign a generated winner or score.

  • Primary Mechanism
  • Direct GHRH receptor agonism → pulsatile GH release from anterior pituitary
  • Modified GHRH analog with enhanced receptor affinity + tissue-specific lipolytic signaling
  • Tesamorelin's structural modification creates dual-action profile sermorelin lacks
  • Plasma Half-Life
  • 10–20 minutes (rapid DPP-IV degradation)
  • 26–38 minutes (hexenoic acid protects N-terminus)
  • Longer half-life allows less frequent dosing and sustained GH elevation
  • Visceral Fat Reduction
  • Minimal to none in controlled trials
  • 15–20% reduction in CT-measured VAT over 26 weeks
  • Only tesamorelin demonstrates consistent, significant visceral adipose loss
  • IGF-1 Elevation
  • 40–60% increase from baseline at therapeutic dose
  • 80–120 ng/mL absolute increase, dose-dependent
  • Both effective; tesamorelin produces higher sustained IGF-1 levels
  • FDA Status
  • Approved for diagnostic GH testing only
  • Approved for HIV-associated lipodystrophy (2010)
  • Tesamorelin has formal regulatory pathway for body composition indication
  • Typical Research Dose
  • 1–2 mcg/kg SC daily, typically before sleep
  • 2 mg SC daily, administered in morning
  • Sermorelin dosed by weight; tesamorelin uses fixed milligram dose
  • Storage Stability
  • Lyophilized: −20°C; reconstituted: 2–8°C, use within 14 days
  • Lyophilized: −20°C; reconstituted: 2–8°C, use within 28 days
  • Tesamorelin's modification confers modest stability advantage post-reconstitution
  • Cost (Research Grade)
  • $180–$320 per 5 mg vial depending on purity certification
  • $280–$450 per 2 mg vial (higher synthesis complexity)
  • Sermorelin offers better cost-per-dose for non-adipose research applications
More references

Related material